chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 57.0
Sex: M
Vaccine: FLU(H1N1)
Symptoms: Antinuclear antibody positive, Asthenia, Blood pressure increased, Blood product transfusion, Bronchitis
Clinical narrative: Initial report received on 08 January 2010 from the Center for Disease Control (CDC), VAERS reference number 371931-1. A 57 year old male patient received Influenza A (H1N1) 2009 Monovalent Vaccine - Preservative (lot number UP017AA) on 10 November 2009. Within four weeks prior to 10 November 2009, the patient received FLUVIRIN (manufacturer Novartis, lot number 88634); a specific date was not reported. The patient's medical history included appendectomy, inguinal herniorrhaphy, and occasional reflux. The patient presented to the emergency department and was admitted with dysphonic nasal speech and upper body weakness of 3 days duration; initial symptoms started 24 days after vaccination. A tentative diagnosis of Miller Fisher variant of  GUILLAIN-BARRE Syndrome was made by the neurologist. Elevated blood pressure was noted. Additional symptoms included diplopia, right gaze, bilateral cranial nerve VI global weakness, dysphagia, and paresthesias fingertips. The patient had a recent URI/pharyngitis/sore throat which progressed to bronchitis. Decreased active range of motion secondary to weakness, decreased tendon reflexes, and tissue texture changes mid left thoracic paraspinal muscles were noted. Treatment included IVIG administration. Additional symptoms included suboccipital and frontal headaches, migraine, hypertension, oral candida/candida of the tongue, and mild renal impairment. The patient also complained of toe swelling. Laboratory data was significant for ANA screening positive titer 1:320 (H). The patient was hospitalized from 06 December 2009 to 11 December 2009 (also reported as 06 December 2009 to 15 December 2009). The final assessment was Miller Fisher variant GUILLAIN-BARRE Syndrome. The patient's recovery status was not provided; however, the patient was in stable condition upon date of discharge. Documents held by sender: None.
Age: 57.0
Sex: M
Vaccine: FLU(H1N1)
Symptoms: Cranial nerve disorder, Diplopia, Dysphagia, Dysphonia, Gaze palsy
Clinical narrative: Initial report received on 08 January 2010 from the Center for Disease Control (CDC), VAERS reference number 371931-1. A 57 year old male patient received Influenza A (H1N1) 2009 Monovalent Vaccine - Preservative (lot number UP017AA) on 10 November 2009. Within four weeks prior to 10 November 2009, the patient received FLUVIRIN (manufacturer Novartis, lot number 88634); a specific date was not reported. The patient's medical history included appendectomy, inguinal herniorrhaphy, and occasional reflux. The patient presented to the emergency department and was admitted with dysphonic nasal speech and upper body weakness of 3 days duration; initial symptoms started 24 days after vaccination. A tentative diagnosis of Miller Fisher variant of  GUILLAIN-BARRE Syndrome was made by the neurologist. Elevated blood pressure was noted. Additional symptoms included diplopia, right gaze, bilateral cranial nerve VI global weakness, dysphagia, and paresthesias fingertips. The patient had a recent URI/pharyngitis/sore throat which progressed to bronchitis. Decreased active range of motion secondary to weakness, decreased tendon reflexes, and tissue texture changes mid left thoracic paraspinal muscles were noted. Treatment included IVIG administration. Additional symptoms included suboccipital and frontal headaches, migraine, hypertension, oral candida/candida of the tongue, and mild renal impairment. The patient also complained of toe swelling. Laboratory data was significant for ANA screening positive titer 1:320 (H). The patient was hospitalized from 06 December 2009 to 11 December 2009 (also reported as 06 December 2009 to 15 December 2009). The final assessment was Miller Fisher variant GUILLAIN-BARRE Syndrome. The patient's recovery status was not provided; however, the patient was in stable condition upon date of discharge. Documents held by sender: None.
Age: 57.0
Sex: M
Vaccine: FLU(H1N1)
Symptoms: Guillain-Barre syndrome, Headache, Hypertension, Hyporeflexia, Joint range of motion decreased
Clinical narrative: Initial report received on 08 January 2010 from the Center for Disease Control (CDC), VAERS reference number 371931-1. A 57 year old male patient received Influenza A (H1N1) 2009 Monovalent Vaccine - Preservative (lot number UP017AA) on 10 November 2009. Within four weeks prior to 10 November 2009, the patient received FLUVIRIN (manufacturer Novartis, lot number 88634); a specific date was not reported. The patient's medical history included appendectomy, inguinal herniorrhaphy, and occasional reflux. The patient presented to the emergency department and was admitted with dysphonic nasal speech and upper body weakness of 3 days duration; initial symptoms started 24 days after vaccination. A tentative diagnosis of Miller Fisher variant of  GUILLAIN-BARRE Syndrome was made by the neurologist. Elevated blood pressure was noted. Additional symptoms included diplopia, right gaze, bilateral cranial nerve VI global weakness, dysphagia, and paresthesias fingertips. The patient had a recent URI/pharyngitis/sore throat which progressed to bronchitis. Decreased active range of motion secondary to weakness, decreased tendon reflexes, and tissue texture changes mid left thoracic paraspinal muscles were noted. Treatment included IVIG administration. Additional symptoms included suboccipital and frontal headaches, migraine, hypertension, oral candida/candida of the tongue, and mild renal impairment. The patient also complained of toe swelling. Laboratory data was significant for ANA screening positive titer 1:320 (H). The patient was hospitalized from 06 December 2009 to 11 December 2009 (also reported as 06 December 2009 to 15 December 2009). The final assessment was Miller Fisher variant GUILLAIN-BARRE Syndrome. The patient's recovery status was not provided; however, the patient was in stable condition upon date of discharge. Documents held by sender: None.
Age: 57.0
Sex: M
Vaccine: FLU(H1N1)
Symptoms: Migraine, Miller Fisher syndrome, Muscle injury, Oedema peripheral, Oral candidiasis
Clinical narrative: Initial report received on 08 January 2010 from the Center for Disease Control (CDC), VAERS reference number 371931-1. A 57 year old male patient received Influenza A (H1N1) 2009 Monovalent Vaccine - Preservative (lot number UP017AA) on 10 November 2009. Within four weeks prior to 10 November 2009, the patient received FLUVIRIN (manufacturer Novartis, lot number 88634); a specific date was not reported. The patient's medical history included appendectomy, inguinal herniorrhaphy, and occasional reflux. The patient presented to the emergency department and was admitted with dysphonic nasal speech and upper body weakness of 3 days duration; initial symptoms started 24 days after vaccination. A tentative diagnosis of Miller Fisher variant of  GUILLAIN-BARRE Syndrome was made by the neurologist. Elevated blood pressure was noted. Additional symptoms included diplopia, right gaze, bilateral cranial nerve VI global weakness, dysphagia, and paresthesias fingertips. The patient had a recent URI/pharyngitis/sore throat which progressed to bronchitis. Decreased active range of motion secondary to weakness, decreased tendon reflexes, and tissue texture changes mid left thoracic paraspinal muscles were noted. Treatment included IVIG administration. Additional symptoms included suboccipital and frontal headaches, migraine, hypertension, oral candida/candida of the tongue, and mild renal impairment. The patient also complained of toe swelling. Laboratory data was significant for ANA screening positive titer 1:320 (H). The patient was hospitalized from 06 December 2009 to 11 December 2009 (also reported as 06 December 2009 to 15 December 2009). The final assessment was Miller Fisher variant GUILLAIN-BARRE Syndrome. The patient's recovery status was not provided; however, the patient was in stable condition upon date of discharge. Documents held by sender: None.
Age: 57.0
Sex: M
Vaccine: FLU(H1N1)
Symptoms: Oropharyngeal pain, Paraesthesia, Pharyngitis, Renal impairment, Soft tissue disorder
Clinical narrative: Initial report received on 08 January 2010 from the Center for Disease Control (CDC), VAERS reference number 371931-1. A 57 year old male patient received Influenza A (H1N1) 2009 Monovalent Vaccine - Preservative (lot number UP017AA) on 10 November 2009. Within four weeks prior to 10 November 2009, the patient received FLUVIRIN (manufacturer Novartis, lot number 88634); a specific date was not reported. The patient's medical history included appendectomy, inguinal herniorrhaphy, and occasional reflux. The patient presented to the emergency department and was admitted with dysphonic nasal speech and upper body weakness of 3 days duration; initial symptoms started 24 days after vaccination. A tentative diagnosis of Miller Fisher variant of  GUILLAIN-BARRE Syndrome was made by the neurologist. Elevated blood pressure was noted. Additional symptoms included diplopia, right gaze, bilateral cranial nerve VI global weakness, dysphagia, and paresthesias fingertips. The patient had a recent URI/pharyngitis/sore throat which progressed to bronchitis. Decreased active range of motion secondary to weakness, decreased tendon reflexes, and tissue texture changes mid left thoracic paraspinal muscles were noted. Treatment included IVIG administration. Additional symptoms included suboccipital and frontal headaches, migraine, hypertension, oral candida/candida of the tongue, and mild renal impairment. The patient also complained of toe swelling. Laboratory data was significant for ANA screening positive titer 1:320 (H). The patient was hospitalized from 06 December 2009 to 11 December 2009 (also reported as 06 December 2009 to 15 December 2009). The final assessment was Miller Fisher variant GUILLAIN-BARRE Syndrome. The patient's recovery status was not provided; however, the patient was in stable condition upon date of discharge. Documents held by sender: None.
Age: 57.0
Sex: M
Vaccine: FLU(H1N1)
Symptoms: Upper respiratory tract infection
Clinical narrative: Initial report received on 08 January 2010 from the Center for Disease Control (CDC), VAERS reference number 371931-1. A 57 year old male patient received Influenza A (H1N1) 2009 Monovalent Vaccine - Preservative (lot number UP017AA) on 10 November 2009. Within four weeks prior to 10 November 2009, the patient received FLUVIRIN (manufacturer Novartis, lot number 88634); a specific date was not reported. The patient's medical history included appendectomy, inguinal herniorrhaphy, and occasional reflux. The patient presented to the emergency department and was admitted with dysphonic nasal speech and upper body weakness of 3 days duration; initial symptoms started 24 days after vaccination. A tentative diagnosis of Miller Fisher variant of  GUILLAIN-BARRE Syndrome was made by the neurologist. Elevated blood pressure was noted. Additional symptoms included diplopia, right gaze, bilateral cranial nerve VI global weakness, dysphagia, and paresthesias fingertips. The patient had a recent URI/pharyngitis/sore throat which progressed to bronchitis. Decreased active range of motion secondary to weakness, decreased tendon reflexes, and tissue texture changes mid left thoracic paraspinal muscles were noted. Treatment included IVIG administration. Additional symptoms included suboccipital and frontal headaches, migraine, hypertension, oral candida/candida of the tongue, and mild renal impairment. The patient also complained of toe swelling. Laboratory data was significant for ANA screening positive titer 1:320 (H). The patient was hospitalized from 06 December 2009 to 11 December 2009 (also reported as 06 December 2009 to 15 December 2009). The final assessment was Miller Fisher variant GUILLAIN-BARRE Syndrome. The patient's recovery status was not provided; however, the patient was in stable condition upon date of discharge. Documents held by sender: None.
Age: 16.0
Sex: M
Vaccine: FLU(H1N1)
Symptoms: Asthenia, Ataxia, Balance disorder, Blood product transfusion, Brain scan normal
Clinical narrative: Initial report was received on 08 January 2010 from the Centers for Disease Control and Prevention (CDC); VAERS reference number 372283-1. A 16-year-old male patient received INFLUENZA A H1N1 2009 Monovalent Vaccine - Preservative (lot number UP025AA) on 04 December 2009. His past medical history was significant for Hodgkin's lymphoma (age 4). Four days post-vaccination, the patient presented to the emergency department with arm and leg weakness and pain and had complaints of ascending paralysis, ataxia, dizziness, headache, loss of balance, loss of strength, and he was unable to stand on his own. Guillain-Barre Syndrome was suspected. The patient was hospitalized. Upon admission, a spinal tap was performed and the patient was started on IV gamma globulin 25mg daily for five days. Spinal tap results were within normal limits (M-TP 21 mg/dL, Glucose - 21, mg/dL, RBC - 1, WBC - 1). Other labs and diagnostics included CBC, UA, and a CT scan of the brain, which were within normal limits. According to medical records received by the CDC, the patient had been diagnosed with suspected Guillain-Barre Syndrome. Additionally, the diagnosis of cerebellitis was evaluated as s/p vaccination. At the time of discharge, the patient could walk with assistance and he had been alert and oriented with a mild headache. The patient had not recovered. Documents held by sender: None.
Age: 16.0
Sex: M
Vaccine: FLU(H1N1)
Symptoms: CSF glucose normal, CSF test normal, Dizziness, Dysstasia, Encephalitis
Clinical narrative: Initial report was received on 08 January 2010 from the Centers for Disease Control and Prevention (CDC); VAERS reference number 372283-1. A 16-year-old male patient received INFLUENZA A H1N1 2009 Monovalent Vaccine - Preservative (lot number UP025AA) on 04 December 2009. His past medical history was significant for Hodgkin's lymphoma (age 4). Four days post-vaccination, the patient presented to the emergency department with arm and leg weakness and pain and had complaints of ascending paralysis, ataxia, dizziness, headache, loss of balance, loss of strength, and he was unable to stand on his own. Guillain-Barre Syndrome was suspected. The patient was hospitalized. Upon admission, a spinal tap was performed and the patient was started on IV gamma globulin 25mg daily for five days. Spinal tap results were within normal limits (M-TP 21 mg/dL, Glucose - 21, mg/dL, RBC - 1, WBC - 1). Other labs and diagnostics included CBC, UA, and a CT scan of the brain, which were within normal limits. According to medical records received by the CDC, the patient had been diagnosed with suspected Guillain-Barre Syndrome. Additionally, the diagnosis of cerebellitis was evaluated as s/p vaccination. At the time of discharge, the patient could walk with assistance and he had been alert and oriented with a mild headache. The patient had not recovered. Documents held by sender: None.
Age: 16.0
Sex: M
Vaccine: FLU(H1N1)
Symptoms: Gait disturbance, Guillain-Barre syndrome, Headache, Muscular weakness, Pain in extremity
Clinical narrative: Initial report was received on 08 January 2010 from the Centers for Disease Control and Prevention (CDC); VAERS reference number 372283-1. A 16-year-old male patient received INFLUENZA A H1N1 2009 Monovalent Vaccine - Preservative (lot number UP025AA) on 04 December 2009. His past medical history was significant for Hodgkin's lymphoma (age 4). Four days post-vaccination, the patient presented to the emergency department with arm and leg weakness and pain and had complaints of ascending paralysis, ataxia, dizziness, headache, loss of balance, loss of strength, and he was unable to stand on his own. Guillain-Barre Syndrome was suspected. The patient was hospitalized. Upon admission, a spinal tap was performed and the patient was started on IV gamma globulin 25mg daily for five days. Spinal tap results were within normal limits (M-TP 21 mg/dL, Glucose - 21, mg/dL, RBC - 1, WBC - 1). Other labs and diagnostics included CBC, UA, and a CT scan of the brain, which were within normal limits. According to medical records received by the CDC, the patient had been diagnosed with suspected Guillain-Barre Syndrome. Additionally, the diagnosis of cerebellitis was evaluated as s/p vaccination. At the time of discharge, the patient could walk with assistance and he had been alert and oriented with a mild headache. The patient had not recovered. Documents held by sender: None.
Age: 16.0
Sex: M
Vaccine: FLU(H1N1)
Symptoms: Red blood cell count normal, Urine analysis normal
Clinical narrative: Initial report was received on 08 January 2010 from the Centers for Disease Control and Prevention (CDC); VAERS reference number 372283-1. A 16-year-old male patient received INFLUENZA A H1N1 2009 Monovalent Vaccine - Preservative (lot number UP025AA) on 04 December 2009. His past medical history was significant for Hodgkin's lymphoma (age 4). Four days post-vaccination, the patient presented to the emergency department with arm and leg weakness and pain and had complaints of ascending paralysis, ataxia, dizziness, headache, loss of balance, loss of strength, and he was unable to stand on his own. Guillain-Barre Syndrome was suspected. The patient was hospitalized. Upon admission, a spinal tap was performed and the patient was started on IV gamma globulin 25mg daily for five days. Spinal tap results were within normal limits (M-TP 21 mg/dL, Glucose - 21, mg/dL, RBC - 1, WBC - 1). Other labs and diagnostics included CBC, UA, and a CT scan of the brain, which were within normal limits. According to medical records received by the CDC, the patient had been diagnosed with suspected Guillain-Barre Syndrome. Additionally, the diagnosis of cerebellitis was evaluated as s/p vaccination. At the time of discharge, the patient could walk with assistance and he had been alert and oriented with a mild headache. The patient had not recovered. Documents held by sender: None.
Age: 2.0
Sex: F
Vaccine: FLU(H1N1), FLU3
Symptoms: Guillain-Barre syndrome
Clinical narrative: Initial report was received on 08 January 2010 from the CDC, VAERS reference number 372442-1. A 2-year-old female patient with no reported medical history received an injection of FLUZONE (lot number U3260AA) and H1N1 (lot number UP012AA) on 06 November 2009. The time to onset for initial symptoms of Guillain Barre Syndrome was reported as 22 days after vaccination. The patient was hospitalized 7 days later on 05 December 2009. Her recovery status was unknown at the time of the report. Documents held by sender: None.
Age: 34.0
Sex: F
Vaccine: FLU(H1N1)
Symptoms: Dizziness, Electrocardiogram normal, Full blood count, International normalised ratio, Laboratory test
Clinical narrative: 2 days after she went to the ER stating she felt faint while seeing a patient no loss of consicouness, but almost passed out. BP 108/66 Exam normal. Given- Normal saline bolus 1000 cc over 2 hrs felt better - orthostatic BP- WNL.
Age: 57.0
Sex: M
Vaccine: FLU(H1N1)
Symptoms: Activities of daily living impaired, Aspartate aminotransferase increased, Blood creatine phosphokinase increased, Blood product transfusion, Botulism
Clinical narrative: Initial report was received 08 January 2010 from the CDC, VAERS reference number 373204-1. A 57-year-old male patient had received a dose injection of H1N1, lot number UP005AA (route and site not reported) on 26 October 2009. The patient's medical history included obesity, diverticulosis, osteoarthritis, elevated PSA and prostatic biopsy. Initial symptoms started 33 days after vaccination. The patient was hospitalized from 30 November 2009 to 13 December 2009. The patient presented with progressive muscle weakness; proximal upper and lower extremity weakness. It was reported that the patient ate uncooked salmon, peanuts, and drank honey recently. Symptoms included headaches, chills and difficulty walking, chewing, swallowing and dressing. He also had decreased strength in his facial muscles, proximal shoulders and lower extremities; facial droop and slurred speech. He was unable to raise his arms and had numbness in his feet and hands. Reflexes were decreased. The assessment was Botulism versus Guillain-Barre Syndrome. The patient received corrective treatments with Botulism Trivalent Antitoxin (manufacturer unknown, lot number not reported) and IVIG; however the patient was unable to tolerate the IVIG. Plasmapheresis was also performed. At an unspecified time, the patient experienced a fall. It was also reported that the patient used walker and experienced tachycardia when ambulating. Laboratory and diagnostic test results included CSF (normal), EMG (abnormal-proximal muscle weakness), chest x-ray (abnormal), RBC 3.7 mil/mcl (L), HGB 11.4 g/dl (L), HCT 32, AST increased, CPK increased. At the time of the report, the patient's recovery status was unknown.
Age: 57.0
Sex: M
Vaccine: FLU(H1N1)
Symptoms: CSF cell count normal, CSF test normal, Chest X-ray abnormal, Chills, Dysarthria
Clinical narrative: Initial report was received 08 January 2010 from the CDC, VAERS reference number 373204-1. A 57-year-old male patient had received a dose injection of H1N1, lot number UP005AA (route and site not reported) on 26 October 2009. The patient's medical history included obesity, diverticulosis, osteoarthritis, elevated PSA and prostatic biopsy. Initial symptoms started 33 days after vaccination. The patient was hospitalized from 30 November 2009 to 13 December 2009. The patient presented with progressive muscle weakness; proximal upper and lower extremity weakness. It was reported that the patient ate uncooked salmon, peanuts, and drank honey recently. Symptoms included headaches, chills and difficulty walking, chewing, swallowing and dressing. He also had decreased strength in his facial muscles, proximal shoulders and lower extremities; facial droop and slurred speech. He was unable to raise his arms and had numbness in his feet and hands. Reflexes were decreased. The assessment was Botulism versus Guillain-Barre Syndrome. The patient received corrective treatments with Botulism Trivalent Antitoxin (manufacturer unknown, lot number not reported) and IVIG; however the patient was unable to tolerate the IVIG. Plasmapheresis was also performed. At an unspecified time, the patient experienced a fall. It was also reported that the patient used walker and experienced tachycardia when ambulating. Laboratory and diagnostic test results included CSF (normal), EMG (abnormal-proximal muscle weakness), chest x-ray (abnormal), RBC 3.7 mil/mcl (L), HGB 11.4 g/dl (L), HCT 32, AST increased, CPK increased. At the time of the report, the patient's recovery status was unknown.
Age: 57.0
Sex: M
Vaccine: FLU(H1N1)
Symptoms: Dysphagia, Electromyogram abnormal, Facial palsy, Facial paresis, Fall
Clinical narrative: Initial report was received 08 January 2010 from the CDC, VAERS reference number 373204-1. A 57-year-old male patient had received a dose injection of H1N1, lot number UP005AA (route and site not reported) on 26 October 2009. The patient's medical history included obesity, diverticulosis, osteoarthritis, elevated PSA and prostatic biopsy. Initial symptoms started 33 days after vaccination. The patient was hospitalized from 30 November 2009 to 13 December 2009. The patient presented with progressive muscle weakness; proximal upper and lower extremity weakness. It was reported that the patient ate uncooked salmon, peanuts, and drank honey recently. Symptoms included headaches, chills and difficulty walking, chewing, swallowing and dressing. He also had decreased strength in his facial muscles, proximal shoulders and lower extremities; facial droop and slurred speech. He was unable to raise his arms and had numbness in his feet and hands. Reflexes were decreased. The assessment was Botulism versus Guillain-Barre Syndrome. The patient received corrective treatments with Botulism Trivalent Antitoxin (manufacturer unknown, lot number not reported) and IVIG; however the patient was unable to tolerate the IVIG. Plasmapheresis was also performed. At an unspecified time, the patient experienced a fall. It was also reported that the patient used walker and experienced tachycardia when ambulating. Laboratory and diagnostic test results included CSF (normal), EMG (abnormal-proximal muscle weakness), chest x-ray (abnormal), RBC 3.7 mil/mcl (L), HGB 11.4 g/dl (L), HCT 32, AST increased, CPK increased. At the time of the report, the patient's recovery status was unknown.
Age: 57.0
Sex: M
Vaccine: FLU(H1N1)
Symptoms: Full blood count abnormal, Gait disturbance, Guillain-Barre syndrome, Haematocrit decreased, Haemoglobin decreased
Clinical narrative: Initial report was received 08 January 2010 from the CDC, VAERS reference number 373204-1. A 57-year-old male patient had received a dose injection of H1N1, lot number UP005AA (route and site not reported) on 26 October 2009. The patient's medical history included obesity, diverticulosis, osteoarthritis, elevated PSA and prostatic biopsy. Initial symptoms started 33 days after vaccination. The patient was hospitalized from 30 November 2009 to 13 December 2009. The patient presented with progressive muscle weakness; proximal upper and lower extremity weakness. It was reported that the patient ate uncooked salmon, peanuts, and drank honey recently. Symptoms included headaches, chills and difficulty walking, chewing, swallowing and dressing. He also had decreased strength in his facial muscles, proximal shoulders and lower extremities; facial droop and slurred speech. He was unable to raise his arms and had numbness in his feet and hands. Reflexes were decreased. The assessment was Botulism versus Guillain-Barre Syndrome. The patient received corrective treatments with Botulism Trivalent Antitoxin (manufacturer unknown, lot number not reported) and IVIG; however the patient was unable to tolerate the IVIG. Plasmapheresis was also performed. At an unspecified time, the patient experienced a fall. It was also reported that the patient used walker and experienced tachycardia when ambulating. Laboratory and diagnostic test results included CSF (normal), EMG (abnormal-proximal muscle weakness), chest x-ray (abnormal), RBC 3.7 mil/mcl (L), HGB 11.4 g/dl (L), HCT 32, AST increased, CPK increased. At the time of the report, the patient's recovery status was unknown.
Age: 57.0
Sex: M
Vaccine: FLU(H1N1)
Symptoms: Headache, Hypoaesthesia, Hyporeflexia, Mastication disorder, Mobility decreased
Clinical narrative: Initial report was received 08 January 2010 from the CDC, VAERS reference number 373204-1. A 57-year-old male patient had received a dose injection of H1N1, lot number UP005AA (route and site not reported) on 26 October 2009. The patient's medical history included obesity, diverticulosis, osteoarthritis, elevated PSA and prostatic biopsy. Initial symptoms started 33 days after vaccination. The patient was hospitalized from 30 November 2009 to 13 December 2009. The patient presented with progressive muscle weakness; proximal upper and lower extremity weakness. It was reported that the patient ate uncooked salmon, peanuts, and drank honey recently. Symptoms included headaches, chills and difficulty walking, chewing, swallowing and dressing. He also had decreased strength in his facial muscles, proximal shoulders and lower extremities; facial droop and slurred speech. He was unable to raise his arms and had numbness in his feet and hands. Reflexes were decreased. The assessment was Botulism versus Guillain-Barre Syndrome. The patient received corrective treatments with Botulism Trivalent Antitoxin (manufacturer unknown, lot number not reported) and IVIG; however the patient was unable to tolerate the IVIG. Plasmapheresis was also performed. At an unspecified time, the patient experienced a fall. It was also reported that the patient used walker and experienced tachycardia when ambulating. Laboratory and diagnostic test results included CSF (normal), EMG (abnormal-proximal muscle weakness), chest x-ray (abnormal), RBC 3.7 mil/mcl (L), HGB 11.4 g/dl (L), HCT 32, AST increased, CPK increased. At the time of the report, the patient's recovery status was unknown.
Age: 57.0
Sex: M
Vaccine: FLU(H1N1)
Symptoms: Muscular weakness, Occult blood, Plasmapheresis, Red blood cell count decreased, Tachycardia
Clinical narrative: Initial report was received 08 January 2010 from the CDC, VAERS reference number 373204-1. A 57-year-old male patient had received a dose injection of H1N1, lot number UP005AA (route and site not reported) on 26 October 2009. The patient's medical history included obesity, diverticulosis, osteoarthritis, elevated PSA and prostatic biopsy. Initial symptoms started 33 days after vaccination. The patient was hospitalized from 30 November 2009 to 13 December 2009. The patient presented with progressive muscle weakness; proximal upper and lower extremity weakness. It was reported that the patient ate uncooked salmon, peanuts, and drank honey recently. Symptoms included headaches, chills and difficulty walking, chewing, swallowing and dressing. He also had decreased strength in his facial muscles, proximal shoulders and lower extremities; facial droop and slurred speech. He was unable to raise his arms and had numbness in his feet and hands. Reflexes were decreased. The assessment was Botulism versus Guillain-Barre Syndrome. The patient received corrective treatments with Botulism Trivalent Antitoxin (manufacturer unknown, lot number not reported) and IVIG; however the patient was unable to tolerate the IVIG. Plasmapheresis was also performed. At an unspecified time, the patient experienced a fall. It was also reported that the patient used walker and experienced tachycardia when ambulating. Laboratory and diagnostic test results included CSF (normal), EMG (abnormal-proximal muscle weakness), chest x-ray (abnormal), RBC 3.7 mil/mcl (L), HGB 11.4 g/dl (L), HCT 32, AST increased, CPK increased. At the time of the report, the patient's recovery status was unknown.
Age: 57.0
Sex: M
Vaccine: FLU(H1N1)
Symptoms: Walking aid user
Clinical narrative: Initial report was received 08 January 2010 from the CDC, VAERS reference number 373204-1. A 57-year-old male patient had received a dose injection of H1N1, lot number UP005AA (route and site not reported) on 26 October 2009. The patient's medical history included obesity, diverticulosis, osteoarthritis, elevated PSA and prostatic biopsy. Initial symptoms started 33 days after vaccination. The patient was hospitalized from 30 November 2009 to 13 December 2009. The patient presented with progressive muscle weakness; proximal upper and lower extremity weakness. It was reported that the patient ate uncooked salmon, peanuts, and drank honey recently. Symptoms included headaches, chills and difficulty walking, chewing, swallowing and dressing. He also had decreased strength in his facial muscles, proximal shoulders and lower extremities; facial droop and slurred speech. He was unable to raise his arms and had numbness in his feet and hands. Reflexes were decreased. The assessment was Botulism versus Guillain-Barre Syndrome. The patient received corrective treatments with Botulism Trivalent Antitoxin (manufacturer unknown, lot number not reported) and IVIG; however the patient was unable to tolerate the IVIG. Plasmapheresis was also performed. At an unspecified time, the patient experienced a fall. It was also reported that the patient used walker and experienced tachycardia when ambulating. Laboratory and diagnostic test results included CSF (normal), EMG (abnormal-proximal muscle weakness), chest x-ray (abnormal), RBC 3.7 mil/mcl (L), HGB 11.4 g/dl (L), HCT 32, AST increased, CPK increased. At the time of the report, the patient's recovery status was unknown.
Age: 68.0
Sex: F
Vaccine: FLU(H1N1), FLU(H1N1)
Symptoms: Fall, Gait disturbance, Guillain-Barre syndrome, Pain in extremity
Clinical narrative: A 68-year-old female patient received a dose of Influenza A (lot number UP016AA) (routes and sites not reported) on 05 November 2009. The patient's medical history/pre-existing conditions included common variable immune deficiency, IVIG deficiency / IVIG administration monthly, polymyalgia rheumatica, osteoarthritis, bone density test, asthma hypertension, hypercholesterolemia, pulmonary emboli, chronic UTI's (urinary tract infections), colonoscopy, esophagogastroduodenoscopy, esophageal "dilatation", tubal ligation, tonsillectomy, and the remainder of the medical history was truncated. Other medications were reported as "See list"; however no concomitant medications were reported. Three days after vaccinations, the patient "extreme pain in her femurs and fib..fibs" which she did not report right away because she had a lot of arthritic issues. Then she developed increasing problems in walking, described as lurching. She feel over backwards in her closet. She was immediately referred to her PCP (primary care provider). The patient presented with leg and hip pain, she had trouble walking and she had fallen. She also had paresthesias in her legs followed by bone pain. The physician's assessment was muscle weakness on 14 December 2009 and she was referred to a neurologist. Three days later on 17 December 2009 the patient was informed by her doctor that her diagnosis was Guillain-Barre-Syndrome. The event required an emergency room visit (date not reported). At the time of the report the patient's recovery status was unknown. Documents held by sender: None.
Age: 68.0
Sex: F
Vaccine: FLU(H1N1), FLU(H1N1)
Symptoms: Bone pain, Fall, Gait disturbance, Guillain-Barre syndrome, Muscular weakness
Clinical narrative: A 68-year-old female patient received a dose of Influenza A (lot number UP016AA) (routes and sites not reported) on 05 November 2009. The patient's medical history/pre-existing conditions included common variable immune deficiency, IVIG deficiency / IVIG administration monthly, polymyalgia rheumatica, osteoarthritis, bone density test, asthma hypertension, hypercholesterolemia, pulmonary emboli, chronic UTI's (urinary tract infections), colonoscopy, esophagogastroduodenoscopy, esophageal "dilatation", tubal ligation, tonsillectomy, and the remainder of the medical history was truncated. Other medications were reported as "See list"; however no concomitant medications were reported. Three days after vaccinations, the patient "extreme pain in her femurs and fib..fibs" which she did not report right away because she had a lot of arthritic issues. Then she developed increasing problems in walking, described as lurching. She feel over backwards in her closet. She was immediately referred to her PCP (primary care provider). The patient presented with leg and hip pain, she had trouble walking and she had fallen. She also had paresthesias in her legs followed by bone pain. The physician's assessment was muscle weakness on 14 December 2009 and she was referred to a neurologist. Three days later on 17 December 2009 the patient was informed by her doctor that her diagnosis was Guillain-Barre-Syndrome. The event required an emergency room visit (date not reported). At the time of the report the patient's recovery status was unknown. Documents held by sender: None.
Age: 68.0
Sex: F
Vaccine: FLU(H1N1), FLU(H1N1)
Symptoms: Paraesthesia
Clinical narrative: A 68-year-old female patient received a dose of Influenza A (lot number UP016AA) (routes and sites not reported) on 05 November 2009. The patient's medical history/pre-existing conditions included common variable immune deficiency, IVIG deficiency / IVIG administration monthly, polymyalgia rheumatica, osteoarthritis, bone density test, asthma hypertension, hypercholesterolemia, pulmonary emboli, chronic UTI's (urinary tract infections), colonoscopy, esophagogastroduodenoscopy, esophageal "dilatation", tubal ligation, tonsillectomy, and the remainder of the medical history was truncated. Other medications were reported as "See list"; however no concomitant medications were reported. Three days after vaccinations, the patient "extreme pain in her femurs and fib..fibs" which she did not report right away because she had a lot of arthritic issues. Then she developed increasing problems in walking, described as lurching. She feel over backwards in her closet. She was immediately referred to her PCP (primary care provider). The patient presented with leg and hip pain, she had trouble walking and she had fallen. She also had paresthesias in her legs followed by bone pain. The physician's assessment was muscle weakness on 14 December 2009 and she was referred to a neurologist. Three days later on 17 December 2009 the patient was informed by her doctor that her diagnosis was Guillain-Barre-Syndrome. The event required an emergency room visit (date not reported). At the time of the report the patient's recovery status was unknown. Documents held by sender: None.
Age: 35.0
Sex: M
Vaccine: FLU(H1N1)
Symptoms: Blood test, Chest X-ray, Computerised tomogram, Guillain-Barre syndrome, Hypoaesthesia
Clinical narrative: Initial case received from the Centers for Disease Control and Prevention (CDC) on 08 January 2010, under VAERS ID number 374172-1. A 35-year-old male patient with no known allergies or medical history had received a first dose injection of H1N1 2009 Monovalent Vaccine - Preservative, lot number UF0188AA (route and site not reported) on 04 November 2009. Thirty-five days later, he developed numbness in his arms. Two days later (11 December 2009), the patient presented to the medical center and was subsequently diagnosed with Guillain-Barre. Laboratory and diagnostic tests included a spinal tap, lumbar puncture, chest x-ray, CT scan and blood/fluid testing (dates performed and results were not reported). The patient had been taking PRILOSEC OTC concomitantly. In addition to an extended hospitalization, the reporter considered the seriousness of the event to be life threatening. The patient's recovery status was unknown. Documents held by sender: None.
Age: 35.0
Sex: M
Vaccine: FLU(H1N1)
Symptoms: Laboratory test, Lumbar puncture
Clinical narrative: Initial case received from the Centers for Disease Control and Prevention (CDC) on 08 January 2010, under VAERS ID number 374172-1. A 35-year-old male patient with no known allergies or medical history had received a first dose injection of H1N1 2009 Monovalent Vaccine - Preservative, lot number UF0188AA (route and site not reported) on 04 November 2009. Thirty-five days later, he developed numbness in his arms. Two days later (11 December 2009), the patient presented to the medical center and was subsequently diagnosed with Guillain-Barre. Laboratory and diagnostic tests included a spinal tap, lumbar puncture, chest x-ray, CT scan and blood/fluid testing (dates performed and results were not reported). The patient had been taking PRILOSEC OTC concomitantly. In addition to an extended hospitalization, the reporter considered the seriousness of the event to be life threatening. The patient's recovery status was unknown. Documents held by sender: None.
Age: 40.0
Sex: F
Vaccine: FLU(H1N1)
Symptoms: Dizziness, Guillain-Barre syndrome, Nausea, Vomiting
Clinical narrative: Initial case received from the Centers for Disease Control (CDC) on 08 January 2010, under VAERS ID number 347687-1. A 40-year-old female patient with a history of Crohn's disease had received a first dose injection of Influenza A (H1N1) 2009 Monovalent Vaccine - Preservative, lot number UP002AA (route and site of administration not reported) on 03 November 2009. Forty days later, the patient presented to the emergency room. She was subsequently hospitalized from 13 December to 15 December 2009 for symptoms of dizziness, nausea, and vomiting. The patient was transferred to a second medical center, and then to a third medical center (rationale and length of stays unknown). The patient was diagnosed with GUILLAIN-BARRE Syndrome. Her recovery status was unknown. Documents held by sender: None.
Age: 75.0
Sex: F
Vaccine: FLU(H1N1)
Symptoms: Asthenia, Blood product transfusion, Computerised tomogram, Guillain-Barre syndrome, Intensive care
Clinical narrative: Initial report received on 19 January 2010 from a consumer. A 75 year old female patient with a history of rheumatoid arthritis developed Guillain Barre Syndrome 11 days after receiving H1N1 2009 Monovalent Vaccine - Preservative (lot number UP010AA) on 01 December 2009; route and site of administration were not reported. In September 2009, the patient received a seasonal influenza vaccine (manufacturer and lot number not reported). On 12 December 2009, the patient developed tingling in her toes, generalized muscle aches, paraesthesia, and lost all strength in both arms and legs. The patient was taken to the emergency department by her spouse on 15 December 2009 where the patient was evaluated by a neurologist. The neurologist diagnosed the patient with Guillain Barre Syndrome. The patient was subsequently hospitalized. Initially, the patient was admitted to the intensive care unit and was later transferred to the progressive care unit. The patient underwent 5 plasmapheresis treatments. The patient was transferred back to the intensive care unit after relapsing. The patient was scheduled for 4 more plasmapheresis treatments. The patient remained hospitalized at the time of the report. CAT scan (Computed Tomography), MRI (Magnetic resonance imaging), laboratory work, and ultrasound were completed, however dates of the tests and results were not provided. List of Documents held by Sender: none.
Age: 75.0
Sex: F
Vaccine: FLU(H1N1)
Symptoms: Laboratory test, Myalgia, Nuclear magnetic resonance imaging, Paraesthesia, Plasmapheresis
Clinical narrative: Initial report received on 19 January 2010 from a consumer. A 75 year old female patient with a history of rheumatoid arthritis developed Guillain Barre Syndrome 11 days after receiving H1N1 2009 Monovalent Vaccine - Preservative (lot number UP010AA) on 01 December 2009; route and site of administration were not reported. In September 2009, the patient received a seasonal influenza vaccine (manufacturer and lot number not reported). On 12 December 2009, the patient developed tingling in her toes, generalized muscle aches, paraesthesia, and lost all strength in both arms and legs. The patient was taken to the emergency department by her spouse on 15 December 2009 where the patient was evaluated by a neurologist. The neurologist diagnosed the patient with Guillain Barre Syndrome. The patient was subsequently hospitalized. Initially, the patient was admitted to the intensive care unit and was later transferred to the progressive care unit. The patient underwent 5 plasmapheresis treatments. The patient was transferred back to the intensive care unit after relapsing. The patient was scheduled for 4 more plasmapheresis treatments. The patient remained hospitalized at the time of the report. CAT scan (Computed Tomography), MRI (Magnetic resonance imaging), laboratory work, and ultrasound were completed, however dates of the tests and results were not provided. List of Documents held by Sender: none.
Age: 75.0
Sex: F
Vaccine: FLU(H1N1)
Symptoms: Ultrasound scan
Clinical narrative: Initial report received on 19 January 2010 from a consumer. A 75 year old female patient with a history of rheumatoid arthritis developed Guillain Barre Syndrome 11 days after receiving H1N1 2009 Monovalent Vaccine - Preservative (lot number UP010AA) on 01 December 2009; route and site of administration were not reported. In September 2009, the patient received a seasonal influenza vaccine (manufacturer and lot number not reported). On 12 December 2009, the patient developed tingling in her toes, generalized muscle aches, paraesthesia, and lost all strength in both arms and legs. The patient was taken to the emergency department by her spouse on 15 December 2009 where the patient was evaluated by a neurologist. The neurologist diagnosed the patient with Guillain Barre Syndrome. The patient was subsequently hospitalized. Initially, the patient was admitted to the intensive care unit and was later transferred to the progressive care unit. The patient underwent 5 plasmapheresis treatments. The patient was transferred back to the intensive care unit after relapsing. The patient was scheduled for 4 more plasmapheresis treatments. The patient remained hospitalized at the time of the report. CAT scan (Computed Tomography), MRI (Magnetic resonance imaging), laboratory work, and ultrasound were completed, however dates of the tests and results were not provided. List of Documents held by Sender: none.
Age: 15.0
Sex: M
Vaccine: FLUX(H1N1)
Symptoms: Asthenia, CSF glucose normal, CSF protein increased, Diplopia, Gram stain
Clinical narrative: Initial case received from the Centers for Disease Control (CDC) on 08 January 2010, under VAERS ID number 374943-1. A 15-year-old male patient had received an injection of PANDEMIC INFLUENZA H1N1 VACCINE on 02 December 2009. The patient had been in a motor vehicle accident several days prior - not thought to be spinal cord injury. Twenty days after vaccination, the patient was admitted to the PICU (pediatric intensive care unit) with symptoms of ascending weakness and double vision. The primary diagnosis was GUILLAIN-BARRE Syndrome. Laboratory results included CSF glucose 68 (normal), CSF protein 164 (increased), and CSF Gram stain (negative). In addition to hospitalization, the reporter determined the seriousness of this case to be life threatening. The patient's recovery status was unknown. Documents held by sender: None.
Age: 15.0
Sex: M
Vaccine: FLUX(H1N1)
Symptoms: Guillain-Barre syndrome, Intensive care
Clinical narrative: Initial case received from the Centers for Disease Control (CDC) on 08 January 2010, under VAERS ID number 374943-1. A 15-year-old male patient had received an injection of PANDEMIC INFLUENZA H1N1 VACCINE on 02 December 2009. The patient had been in a motor vehicle accident several days prior - not thought to be spinal cord injury. Twenty days after vaccination, the patient was admitted to the PICU (pediatric intensive care unit) with symptoms of ascending weakness and double vision. The primary diagnosis was GUILLAIN-BARRE Syndrome. Laboratory results included CSF glucose 68 (normal), CSF protein 164 (increased), and CSF Gram stain (negative). In addition to hospitalization, the reporter determined the seriousness of this case to be life threatening. The patient's recovery status was unknown. Documents held by sender: None.
Age: 19.0
Sex: M
Vaccine: FLU(H1N1)
Symptoms: Guillain-Barre syndrome
Clinical narrative: Initial case received from the CDC on 08 January 2010, under VAERS ID number 375064-1. A 19-year-old male patient, with a history of depression, received a dose of H1N1 (lot number not reported) on 14 December 2009. Within 4 weeks prior (unspecified date), he had also received a second dose of Hepatitis A and B vaccine (manufacturer and lot number not reported). On 23 December 2009, 9 days after receiving the H1N1, the patient was admitted to the hospital with a working diagnosis of Guillain-Barre Syndrome. Outcome was unknown, and no additional information was reported.